Prostate cancer Molecular-oriented detection and Treatment of minimal residual disease
Project duration: 01.04.2006 - 30.09.2010 terminated
promet (Collaborative project LSHC-CT-2006-018858) was supported by the
European Commission’s 6th RTD Framework Programme
Prof. Dr. George Thalmann
Department of Urology of the University of Bern
The Department of Urology of the University of Bern - CH
The Institute of Applied Physics of the University of Berne -CH
The Academic Urology Unit of the University of Sheffield - UK
The Department of Urology of the Leiden University Medical Centre - NL
The Clinical Unit - pathophysiology of osteoporosis (INSERM Lyon) - F
The Biochemical Cell Physiology Group of the DKFZ - D
Fukuda Denshi -D
Berthold Technologies - D
Med Discovery - D
tp21 GmbH - D
In the European Union ~200.000 men are diagnosed with prostate cancer every year and that number is likely to increase due to a growing population at risk due to ageing. Because of the progress made in the treatment of the primary tumor, mortality in cancer patients is increasingly linked to metastatic disease; often occult (= micrometastasis or â€minimal residual diseaseâ€) at the time of diagnosis/therapy of the primary tumor.
In this project called PROMET we intend to elucidate the mechanisms and the signature of minimal residual disease in prostate cancer and to develop novel therapeutic approaches to prevent the development of minimal residual disease to overt metastasis.
© Images under copyright of promet consortium.